KIR in Fertility and Pregnancy: How Immune Receptors Shape Maternal Foetal Tolerance
Pregnancy asks the immune system to do something remarkable: protect the body from infection while accepting a developing foetus that carries genetic material from another person. One of the key players in this balancing act is a family of immune receptors called Killer Immunoglobulin-like Receptors, or KIR.
KIR sit on the surface of natural killer cells, especially uterine natural killer cells.
In the uterus, they help shape the placenta, support blood vessel growth, and influence how deeply foetal placental cells embed into the womb lining.
Research into KIR in reproductive immunology is changing how scientists think about implantation, miscarriage, pre-eclampsia, foetal growth restriction, and fertility treatment. The field is still evolving, but it already offers a useful window into why some pregnancies progress smoothly while others face immune-related complications.
What KIR do in the immune system
KIR are receptors found mainly on natural killer cells and some T cells. Their job is to read molecular “identity signals” on other cells. Many of these signals belong to the human leukocyte antigen system, often shortened to HLA.
In pregnancy, the most important interaction is between maternal KIR and HLA-C molecules of the foetus. HLA-C is inherited from both genetic parents and is displayed by trophoblast cells, the specialised foetal cells that form much of the placenta.
KIR can send two broad types of signals:
Inhibitory signals These tell natural killer cells to hold back and avoid damaging healthy cells.
Activating signals These encourage natural killer cells to release factors that can shape tissue growth, blood vessel development, and local immune activity.
This balance matters because trophoblast cells (displaying the HLA-C) must invade the uterine lining enough to remodel maternal blood vessels, but not so much that they cause harm. Uterine natural killer cells help regulate this process.
How KIR shape maternal foetal tolerance
Maternal foetal tolerance means that the immune response becomes highly controlled.
KIR help create this control by guiding how uterine natural killer cells respond to foetal trophoblast cells.
The maternal immune system is asking, “Is this cell safe?” and “How should this tissue grow, and how much support should I provide?” And it gets it's answers from both the maternal side and the foetus.
What is Maternal KIR AA?
If the Mother has KIR AA she has a KIR genotype containing mainly inhibitory KIR receptors and lacking most of the activating KIR genes. Excessive inhibitory signalling can result in less optimal placentation contributing to implantation failure or pregnancy complications.
What is HLA?
Placental trophoblast cells can express HLA-C. These Human leukocyte antigen cells contain two groups HLA-C1 and HLA-C2.
KIR AA - HLA C2 Mismatch
When a mother with KIR AA carries an embryo with paternal HLA-C2, the HLA-C2 molecule can interact strongly with certain KIR receptors on uterine NK cells.
This then produces too much inhibitory signalling (as KIR AA contain mainly inhibitory receptors).
Implantation and Pregnancy Complications
One widely studied pattern involves these maternal KIR AA genotypes and foetal HLA-C2. Research suggests this combination can be linked with higher risk of disorders related to poor placentation (the process by which the placenta forms and attaches to the lining of the uterus during early pregnancy) , including pre-eclampsia and foetal growth restriction.
By contrast, activating receptors such as KIR2DS1 may help offset some risk in certain genetic contexts.
This does not mean any single KIR or HLA result can predict an individual pregnancy outcome. Pregnancy biology is influenced by many factors, including age, medical history, embryo genetics, uterine health, thrombosis risk, infection, and environment. KIR is one part of a wider system.
What recent research is revealing
Recent work has moved beyond the idea that uterine natural killer cells are a single cell type. Single-cell sequencing and spatial biology studies show that the maternal foetal interface contains diverse immune cell populations with different roles across early pregnancy.
Several themes have become clearer:
Uterine natural killer cells are specialised They differ from natural killer cells in the blood. Their role is more about communication, tissue remodelling, and support than direct killing.
Genetic combinations matter Studies continue to link specific maternal KIR and fetal HLA-C pairings with reproductive outcomes, especially those tied to placental development.
Ancestry and population diversity matter KIR genes vary widely between populations. Findings from one group may not apply neatly to another, so diverse research cohorts are essential.
The placenta is an active immune organ Trophoblast cells do not merely avoid detection. They actively engage maternal immune receptors and help shape local tolerance.
Research also suggests KIR pathways may play a role in recurrent miscarriage and implantation failure, though the evidence is more complex than in placental disorders. Some studies find associations, while others show weaker links. Differences in study design, patient selection, fertility treatment history, and genetic background all affect the results.
Clinical applications are promising but not simple
The possibility of KIR testing attracts interest in fertility and high-risk pregnancy care. In theory, KIR and HLA-C genotyping could help identify people at higher risk of immune-mediated placental problems or guide decisions in assisted reproduction.
Potential uses include:
Risk assessment for previous pre-eclampsia or foetal growth restriction
Investigation of recurrent miscarriage after other causes have been excluded
Research-led assessment in repeated implantation failure
Treatment for KIR
Immune therapies include:
steroids
intralipid infusions
intravenous immunoglobulin
filgrastrim
LITT therapy
These vary in evidence quality and some carry risks.
The takeaway
KIR help explain how the immune system supports pregnancy rather than simply tolerating it. Through their interactions with foetal HLA-C, these receptors influence uterine natural killer cell behaviour, placental development, and maternal foetal tolerance.
The science is not yet ready to turn KIR results into simple predictions for every patient. Still, the field is moving towards a more precise view of reproductive health, one that recognises pregnancy as an active immune partnership.
For now, KIR testing and immune-based fertility care should be interpreted with caution and specialist guidance. As research grows, these receptors may become an important part of personalised reproductive medicine, especially for people with a history of placental complications, recurrent loss, or unexplained implantation problems.
Comments